利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

33 条记录 (耗时 0.052 秒)

    ACTIVATORS OF CLASS I HISTONE DEACETLYASES (HDACS) AND USES THEREOF
    4.
    发明申请
    ACTIVATORS OF CLASS I HISTONE DEACETLYASES (HDACS) AND USES THEREOF 审中-公开

    公开(公告)号：US20160280693A1

    公开(公告)日：2016-09-29

    申请号：US14834587

    申请日：2015-08-25

    申请人： Massachusetts Institute of Technology ,  The General Hospital Corporation d/b/a Massachusetts General Hospital

    发明人： Li-Huei Tsai ,  Ling Pan ,  Stephen J. Haggarty ,  Debasis Patnaik

    IPC分类号： C07D405/12

    CPC分类号： C07D405/12 ,  C07C217/58 ,  C07C219/28 ,  C07D307/40 ,  C07D307/52 ,  C07D409/12 ,  C07D411/12 ,  C07D487/04

    摘要： The present invention provides compounds of Formulae (A), (B), (C), and (D), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, pharmaceutical compositions thereof, and kits thereof. The present invention further provides methods of using the compounds to treat or prevent neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (amyotrophic lateral sclerosis), traumatic brain injury, ischemic brain injury, stroke, frontal temporal dementia, Pick's disease, corticobasal degeneration, supra cerebral palsy, prion diseases (e.g., Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker syndrome, Fatal Familial Insomnia, and Kuru), Nieman Pick type C, spinal cerebellar ataxia, spinal muscular dystrophy, ataxia telangiectasia, hippocampal sclerosis, Cockayne syndrome, Werner syndrome, xeroderma pigmentosaum, and Bloom syndrome. In one aspect, the methods include administering to a subject in need of treatment for a neurological disorder a therapeutically effective amount of DAC-001, DAC-002, DAC-003, DAC-009, or DAC-012, or a compound of Formula (A), (B), (C), or (D).

    Activators of class I histone deacetylases (HDACs) and uses thereof
    6.
    发明授权
    Activators of class I histone deacetylases (HDACs) and uses thereof 有权

    公开(公告)号：US11084803B2

    公开(公告)日：2021-08-10

    申请号：US16231324

    申请日：2018-12-21

    申请人： Massachusetts Institute of Technology ,  The General Hospital Corporation

    发明人： Li-Huei Tsai ,  Ling Pan ,  Stephen J. Haggarty ,  Debasis Patnaik

    IPC分类号： C07D405/12 ,  C07D409/12 ,  C07C217/58 ,  C07D411/12 ,  C07D307/40 ,  C07C219/28 ,  C07D307/52 ,  C07D487/04

    摘要： The present invention provides compounds of Formulae (A), (B), (C), and (D), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, pharmaceutical compositions thereof, and kits thereof. The present invention further provides methods of using the compounds to treat or prevent neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (amyotrophic lateral sclerosis), traumatic brain injury, ischemic brain injury, stroke, frontal temporal dementia, Pick's disease, corticobasal degeneration, supra cerebral palsy, prion diseases (e.g., Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker syndrome, Fatal Familial Insomnia, and Kuru), Nieman Pick type C, spinal cerebellar ataxia, spinal muscular dystrophy, ataxia telangiectasia, hippocampal sclerosis, Cockayne syndrome, Werner syndrome, xeroderma pigmentosaum, and Bloom syndrome. In one aspect, the methods include administering to a subject in need of treatment for a neurological disorder a therapeutically effective amount of DAC-001, DAC-002, DAC-003, DAC-009, or DAC-012, or a compound of Formula (A), (B), (C), or (D).

    ACTIVATORS OF CLASS I HISTONE DEACETYLASES (HDACS) AND USES THEREOF
    10.
    发明申请
    ACTIVATORS OF CLASS I HISTONE DEACETYLASES (HDACS) AND USES THEREOF 有权

    公开(公告)号：US20220064151A1

    公开(公告)日：2022-03-03

    申请号：US17397752

    申请日：2021-08-09

    申请人： Massachusetts Institute of Technology ,  The General Hospital Corporation d/b/a Massachusetts General Hospital

    发明人： Li-Huei Tsai ,  Ling Pan ,  Stephen J. Haggarty ,  Debasis Patnaik

    IPC分类号： C07D405/12 ,  C07D307/52 ,  C07D411/12 ,  C07D307/40 ,  C07C217/58 ,  C07D487/04 ,  C07C219/28 ,  C07D409/12

    摘要： The present invention provides compounds of Formulae (A), (B), (C), and (D), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, pharmaceutical compositions thereof, and kits thereof. The present invention further provides methods of using the compounds to treat or prevent neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (amyotrophic lateral sclerosis), traumatic brain injury, ischemic brain injury, stroke, frontal temporal dementia, Pick's disease, corticobasal degeneration, supra cerebral palsy, prion diseases (e.g., Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker syndrome, Fatal Familial Insomnia, and Kuru), Nieman Pick type C, spinal cerebellar ataxia, spinal muscular dystrophy, ataxia telangiectasia, hippocampal sclerosis, Cockayne syndrome, Werner syndrome, xeroderma pigmentosaum, and Bloom syndrome. In one aspect, the methods include administering to a subject in need of treatment for a neurological disorder a therapeutically effective amount of DAC-001, DAC-002, DAC-003, DAC-009, or DAC-012, or a compound of Formula (A), (B), (C), or (D).